x Notable Changes to 2018 Nelson’s Pediatric Antimicrobial Therapy, 24th Edition Antifungals Addition of Candida auris Specific recommendations about antifungal therapeutic drug levels Expanded and new references Most current antifungal activity spectrum table New coccidioidomycosis guidelines incorporated New approaches to mucormycosis included Antimicrobials Antibiotics that are no longer available: cefditoren (Spectracef), ceftibuten (Cedax), penicillin G procaine New daptomycin, entecavir, linezolid, and voriconazole dosing New mebendazole products (Warning: may not yet be commercially available at time of publication) Drug-Resistant Gram-negative Bacilli and Methicillin-Resistant Staphylococcus aureus New discussion and algorithm for selection of antibiotics for presumed or documented Gram-negative, multidrug-resistant pathogens Updated tables for susceptibility of Gram-positive and Gram-negative pathogens Where the newly US Food and Drug Administration–approved pediatric antibiotics for methicillin-resistant Staphylococcus aureus (MRSA) (daptomycin and ceftaroline) fit into treatment strategy with increasing clindamycin resistance References Updated references and reviews for therapy of clinically important infections (eg, community-acquired pneumonia in children, endocarditis, MRSA infections) Updated references for antibiotic prophylaxis to prevent infection following exposures surgical prophylaxis ch00-Nelson-2018_FM_i-x.indd 10 11/20/17 9:25 AM
Previous Page Next Page